As of 2025-05-07, the Intrinsic Value of CRISPR Therapeutics AG (CRSP) is (155.81) USD. This CRSP valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 33.16 USD, the upside of CRISPR Therapeutics AG is -569.90%.
The range of the Intrinsic Value is (364.33) - (102.37) USD
Based on its market price of 33.16 USD and our intrinsic valuation, CRISPR Therapeutics AG (CRSP) is overvalued by 569.90%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (364.33) - (102.37) | (155.81) | -569.9% |
| DCF (Growth 10y) | (89.31) - (278.36) | (128.28) | -486.8% |
| DCF (EBITDA 5y) | (27.78) - (29.79) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (38.39) - (40.73) | (1,234.50) | -123450.0% |
| Fair Value | -21.20 - -21.20 | -21.20 | -163.95% |
| P/E | (42.83) - (53.52) | (46.23) | -239.4% |
| EV/EBITDA | (29.23) - (36.55) | (29.55) | -189.1% |
| EPV | (60.02) - (80.53) | (70.28) | -311.9% |
| DDM - Stable | (33.13) - (135.71) | (84.42) | -354.6% |
| DDM - Multi | (33.36) - (112.48) | (52.20) | -257.4% |
| Market Cap (mil) | 2,863.70 |
| Beta | 1.79 |
| Outstanding shares (mil) | 86.36 |
| Enterprise Value (mil) | 2,565.44 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.89% |
| Cost of Debt | 5.00% |
| WACC | 7.43% |